Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-963272 in NAFLD
NCT04766476Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-963272 in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of adverse events up to 166 days, Incidence of serious adverse events up to 166 days and 4 more. Started Feb 2021; status: terminated.
02
Drugs
BMS-963272
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04766476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04766476.